« Return to News | CROs/Service Providers

PharmaNet Revenues Drop

Thursday, October 30, 2008 10:43 AM

PharmaNet Development is the latest contract research organization (CRO) to release disappointing quarterly earnings as a result of contract cancellations, slow sales and negative foreign exchange rates. Princeton, N.J.-based PharmaNet reported a decrease in direct revenue to $89.2 million, down $10 million, or 10.6%, from the same period last year. Almost $1.5 million of that drop was a result of foreign currency exchange translation.

Although PharmaNet’s early stage segment saw a 13.2% increase in direct revenues, revenues from the late stage segment fell 25% to $46.6 million due to contract cancellations and postponements. The company’s backlog was also down from $579.2 million in June to $521.6 million as of September 30.

In September, PharmaNet cut its full-year revenue forecast more than $30 million to the range of $358 million to $368 million. With the release of third quarter earnings, the company reiterated its September guidance.

PharmaNet’s shares have plunged since September, but in early morning trading Thursday, shares were up 24% to $1.55

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

June 17

New CISCRP study finds patient perceptions of trial participation safety, motives greatly improved

PwC: Volume and value of pharma, diagnostics deals soar in first quarter, as CRO sector waits on sidelines

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

June

Operating environment spurs out-of-the-box ideas
High cost, low success rates drive some sponsors to new monitoring, protocol design, patient-centric initiatives

Private equity interest in CROs could lead to more IPOs
Now flush with cash, many PE investors readying to cash out

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.